Argus Research Reports Cognizant (CTSH) Upgrade and $100.0 Target; Insys Therapeutics (INSY) Shorts Up By 7.19%

February 22, 2018 - By Linda Rogers

Insys Therapeutics Inc (NASDAQ:INSY) had an increase of 7.19% in short interest. INSY’s SI was 12.51 million shares in February as released by FINRA. Its up 7.19% from 11.68M shares previously. With 1.58 million avg volume, 8 days are for Insys Therapeutics Inc (NASDAQ:INSY)’s short sellers to cover INSY’s short positions. The SI to Insys Therapeutics Inc’s float is 66.73%. The stock increased 1.64% or $0.13 during the last trading session, reaching $8.06. About 194,632 shares traded. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 5.69% since February 22, 2017 and is downtrending. It has underperformed by 22.39% the S&P500.

Among 33 analysts covering Cognizant Technology Solutions Corp. (NASDAQ:CTSH), 25 have Buy rating, 1 Sell and 7 Hold. Therefore 76% are positive. Cognizant Technology Solutions Corp. has $100.0 highest and $48 lowest target. $83.73’s average target is 1.80% above currents $82.25 stock price. Cognizant Technology Solutions Corp. had 89 analyst reports since August 6, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, October 10 by Jefferies. The firm earned “Neutral” rating on Thursday, February 8 by Nomura. The stock of Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has “Strong Buy” rating given on Wednesday, November 1 by Needham. The rating was maintained by Cowen & Co with “Buy” on Friday, July 28. Oppenheimer maintained Cognizant Technology Solutions Corporation (NASDAQ:CTSH) rating on Thursday, August 3. Oppenheimer has “Buy” rating and $8000 target. Cowen & Co maintained Cognizant Technology Solutions Corporation (NASDAQ:CTSH) on Wednesday, November 1 with “Buy” rating. Jefferies maintained the stock with “Buy” rating in Wednesday, October 11 report. As per Thursday, September 10, the company rating was initiated by Suntrust Robinson. On Friday, September 8 the stock rating was maintained by Robert W. Baird with “Buy”. The stock of Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has “Buy” rating given on Friday, August 4 by Loop Capital.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $590.93 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.05, from 1.2 in 2017Q2. It improved, as 20 investors sold INSYS Therapeutics, Inc. shares while 20 reduced holdings. 19 funds opened positions while 31 raised stakes. 18.21 million shares or 3.74% more from 17.56 million shares in 2017Q2 were reported. Bnp Paribas Arbitrage Sa reported 18,736 shares. Manufacturers Life Insur Co The stated it has 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). National Bank & Trust Of America De has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY). Whittier Tru has 111 shares for 0% of their portfolio. Alliancebernstein Lp owns 0% invested in INSYS Therapeutics, Inc. (NASDAQ:INSY) for 68,020 shares. Walleye Trading Ltd Limited Liability Company invested in 0% or 30,800 shares. Dimensional Fund Advsr L P reported 460,056 shares. Us Commercial Bank De has invested 0% of its portfolio in INSYS Therapeutics, Inc. (NASDAQ:INSY). Weiss Multi accumulated 34,500 shares. Legal General Pcl owns 7,870 shares or 0% of their US portfolio. Perigon Wealth Limited Liability Corporation holds 57 shares. Sg Americas Ltd reported 11,324 shares. Blackrock Incorporated accumulated 0% or 2.72M shares. Panagora Asset holds 0% or 108,416 shares in its portfolio. Ontario – Canada-based Toronto Dominion Natl Bank has invested 0% in INSYS Therapeutics, Inc. (NASDAQ:INSY).

Among 6 analysts covering Insys Therapeutics (NASDAQ:INSY), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Insys Therapeutics had 22 analyst reports since August 4, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The stock has “Buy” rating by Jefferies on Friday, September 15. Jefferies maintained the shares of INSY in report on Wednesday, October 18 with “Buy” rating. The company was maintained on Friday, June 9 by Jefferies. The stock of INSYS Therapeutics, Inc. (NASDAQ:INSY) earned “Buy” rating by Janney Capital on Thursday, April 14. The company was maintained on Friday, November 3 by Jefferies. The stock has “Buy” rating by RBC Capital Markets on Friday, October 27. The firm has “Buy” rating given on Sunday, August 13 by Jefferies. Piper Jaffray maintained it with “Hold” rating and $1000 target in Tuesday, July 25 report. The firm has “Buy” rating by RBC Capital Markets given on Thursday, June 1.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.27, from 0.76 in 2017Q2. It increased, as 37 investors sold Cognizant Technology Solutions Corporation shares while 296 reduced holdings. 99 funds opened positions while 244 raised stakes. 487.81 million shares or 3.03% less from 503.05 million shares in 2017Q2 were reported. Meiji Yasuda Life Ins Com reported 4,500 shares. Logan Cap Management Inc holds 1.49% or 287,516 shares. The California-based Covington Management has invested 0.01% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Rathbone Brothers Public Limited Company owns 50,683 shares for 0.16% of their portfolio. Twin Tree Management Limited Partnership holds 0.04% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH) for 72,444 shares. Moreover, Rmb Capital Management Ltd Liability has 0.78% invested in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Johnson Financial Gp owns 316 shares. Cap City Trust Commerce Fl holds 34,715 shares or 0.9% of its portfolio. Ancora Advisors Limited Com owns 41,653 shares for 0.18% of their portfolio. Winslow Evans Crocker Inc stated it has 0.67% in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Scharf Invs reported 4.62% of its portfolio in Cognizant Technology Solutions Corporation (NASDAQ:CTSH). Pittenger Anderson reported 62,093 shares. Kentucky Retirement Systems Fund holds 0.2% or 15,574 shares. Cape Cod Five Cents Financial Bank has 29,658 shares for 0.33% of their portfolio. Yhb Invest Inc holds 1.16% or 89,143 shares.

Cognizant Technology Solutions Corporation provides information technology , activities and technology consulting, infrastructure, and business process services worldwide. The company has market cap of $48.50 billion. The firm operates through four divisions: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. It has a 32.51 P/E ratio. The Company’s consulting and technology services include strategy consulting, business and activities consulting, technology strategy and change management, and program management consulting services; application design and development; systems integration; and application testing, consulting, and engineering services, as well as enterprise information management services.

Analysts await Cognizant Technology Solutions Corporation (NASDAQ:CTSH) to report earnings on May, 4. They expect $0.99 EPS, up 25.32% or $0.20 from last year’s $0.79 per share. CTSH’s profit will be $583.74 million for 20.77 P/E if the $0.99 EPS becomes a reality. After $0.96 actual EPS reported by Cognizant Technology Solutions Corporation for the previous quarter, Wall Street now forecasts 3.13% EPS growth.

The stock increased 0.55% or $0.45 during the last trading session, reaching $82.25. About 1.45M shares traded. Cognizant Technology Solutions Corporation (NASDAQ:CTSH) has risen 5.50% since February 22, 2017 and is uptrending. It has underperformed by 11.20% the S&P500.

Since August 28, 2017, it had 0 buys, and 41 sales for $62.43 million activity. 10,000 shares were sold by Kandiah Gajakarnan Vibushanan, worth $798,094 on Wednesday, February 14. Another trade for 479 shares valued at $34,205 was made by Middleton Sean on Friday, September 8. 42,500 Cognizant Technology Solutions Corporation (NASDAQ:CTSH) shares with value of $3.27 million were sold by Mehta Rajeev. The insider CHATTERJEE DEBASHIS sold $125,998. Lennox James Patrick sold $123,456 worth of Cognizant Technology Solutions Corporation (NASDAQ:CTSH) on Thursday, September 7. The insider GOMATAM SUMITHRA sold 8,000 shares worth $592,000. $478,981 worth of Cognizant Technology Solutions Corporation (NASDAQ:CTSH) was sold by fox John nelson JR.